Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier

Journal of Alzheimer's Disease

Volumn 53, Issue 2, 2016, Pages 677-691

  Merino Zamorano, Cristina ^a   Retana, Sofía Fernández De ^a   Montañola, Alex ^a   Batlle, Aina ^a   Saint Pol, Julien ^b   Mysiorek, Caroline ^b   Gosselet, Fabien ^b   Montaner, Joan ^a,c   Hernández Guillamon, Mar ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITÉ D'ARTOIS   (France)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Amyloid beta; ApoA1; ApoJ; Apolipoprotein; Blood brain barrier; Endothelial cells

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; APOLIPOPROTEIN A1; CLUSTERIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; THIOFLAVINE; AMYLOID BETA PROTEIN; APOA1 PROTEIN, HUMAN; CLU PROTEIN, HUMAN; MESSENGER RNA; PEPTIDE FRAGMENT; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1; PROTEIN ZO1; TJP1 PROTEIN, HUMAN;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; BLOOD BRAIN BARRIER; BRAIN; BRAIN CELL; CELL MEMBRANE PERMEABILITY; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MODULATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TRANSPORT; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CAPILLARY PERMEABILITY; CYTOLOGY; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; TRANSFORMED CELL LINE; TRANSPORT AT THE CELLULAR LEVEL;

AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEIN A-I; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL LINE, TRANSFORMED; CEREBRAL CORTEX; CLUSTERIN; ENDOTHELIAL CELLS; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE-1; RNA, MESSENGER; TRANSFECTION; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84979284139     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150976     Document Type: Article

References (60)

1. Yamada M (2000) Cerebral amyloid angiopathy: An overview. Neuropathology 20, 8-22.
2. Attems J (2005) Sporadic cerebral amyloid angiopathy: Pathology, clinical implications, and possible pathomechanisms. Neuropathology 110, 345-359.
3. Mawuenyega KG, SigurdsonW, OvodV, Munsell L, Kasten T, Morris JC,Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
4. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
5. Gosselet F, Saint-Pol J, Candela P, FenartL(2013) Amyloid-peptides, Alzheimer's disease and the blood-brain barrier. Curr Alzheimer Res 10, 1015-1033.
6. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptorrelated protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-1499.
7. Deane R, DuYan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E,Welch D, Manness L, Lin C,Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913.
8. Deane R,Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
9. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteinsEand J in the mouse central nervous system. J Cereb Blood Flow Metab 27, 909-918.
10. Candela P, Gosselet F, Saint-Pol J, Sevin E, Boucau MC, Boulanger E, Cecchelli R, Fenart L (2010) Apicalto-basolateral transport of amyloid-peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 22, 849-859.
11. Zlokovic BV (2004) Clearing amyloid through the bloodbrain barrier. J Neurochem 89, 807-811.
12. Hartz AM, Miller DS, Bauer B (2010) Restoring bloodbrain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 77, 715-723.
13. Elali A, Rivest S (2013) The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. Front Physiol 4, 45.
14. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90, 9649-9653.
15. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT (1995) Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38, 254-259.
16. Charnay Y, Imhof A, Vallet PG, Kovari E, Bouras C, Giannakopoulos P (2012) Clusterin in neurological disorders: Molecular perspectives and clinical relevance. Brain Res Bull 88, 434-443.
17. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, European Alzheimer's Disease Initiative Investigators, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossú P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
18. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J (1996) Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 316, 671-679.
19. Koudinov AR, Matsubara E, Frangione B, Ghiso J (1994) The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 205, 1164-1171.
20. Koudinov AR, Berezov TT, Kumar A, Koudinova NV (1998) Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: Association with apolipoprotein and lipids. Clin Chim Acta 270, 75-84.
21. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM (2011) Plasma clusterin and the risk of Alzheimer disease. JAMA 305, 1322-1326.
22. Matsubara E, Frangione B, Ghiso J (1995) Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem 270, 7563-7567.
23. Wisniewski T, Golabek AA, Kida E,Wisniewski KE, Frangione B (1995) Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 147, 238-244.
24. Harr SD, Uint L, Hollister R, Hyman BT, Mendez AJ (1996) Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J Neurochem 66, 2429-2435.
25. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS (2001) Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40, 3553-3560.
26. Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, Magdesian MH, Grinberg LT, Panizzutti R, Ferreira ST (2009) Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol 41, 1361-1370.
27. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV (2005) IgGassisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25, 11495-11503.
28. Saint-Pol J, Vandenhaute E, Boucau MC, Candela P, Dehouck L, Cecchelli R, Dehouck MP, Fenart L, Gosselet F (2012) Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-peptide accumulation. J Alzheimers Dis 30, 489-503.
29. Saint-Pol J, Candela P, Boucau MC, Fenart L, Gosselet F (2013) Oxysterols decrease apical-to-basolateral transport of Aß peptides via an ABCB1-mediated process in an in vitro Blood-brain barrier model constituted of bovine brain capillary endothelial cells. Brain Res 1517, 1-15.
30. Bachmeier C, Mullan M, Paris D (2010) Characterization and use of human brain microvascular endothelial cells to examine-amyloid exchange in the blood-brain barrier. Cytotechnology 62, 519-529.
31. Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F (2013) A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener Dis 11, 13-21.
32. Coisne C, Dehouck L, Faveeuw C, Delplace Y, Miller F, Landry C, Morissette C, Fenart L, Cecchelli R, Tremblay P, Dehouck B (2005) Mouse syngenic in vitro blood-brain barrier model: A new tool to examine inflammatory events in cerebral endothelium. Lab Invest 85, 734-746.
33. Culot M, Lundquist S, Vanuxeem D, Nion S, Landry C, DelplaceY, DehouckMP, BerezowskiV, Fenart L, Cecchelli R (2008) An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol In Vitro 22, 799-811.
34. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274, 25945-25952.
35. Chen YR, Glabe CG (2006) Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: Stable trimer or tetramer formation by Abeta42. J Biol Chem 281, 24414-24422.
36. Pauwels K, Williams TL, Morris KL, Jonckheere W, Vandersteen A,Kelly G, Schymkowitz J, Rousseau F, Pastore A, Serpell LC, BroersenK(2012) Structural basis for increased toxicity of pathological A-42:A-40 ratios in Alzheimer disease. J Biol Chem 287, 5650-5660.
37. Zlokovic BV,Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J (1996) Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93, 4229-4234.
38. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and bloodbrain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 69, 1995-2004.
39. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV (2008) ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118, 4002-4013.
40. Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T (2007) Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem 103, 2482-2490.
41. Kanekiyo T, Xu H, Bu G (2014) ApoE and A- in Alzheimer's disease: Accidental encounters or partners? Neuron 81, 740-754.
42. Ghiso J, Matsubara E,KoudinovA, Choi-Miura NH, Tomita M, Wisniewski T, Frangione B (1993) The cerebrospinalfluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293, 27-30.
43. Balazs Z, Panzenboeck U, Hammer A, Sovic A, Quehenberger O, Malle E, Sattler W (2004) Uptake and transport of high-density lipoprotein (HDL) and HDL-associated alpha-tocopherol by an in vitro blood-brain barrier model. J Neurochem 89, 939-950.
44. Dietschy JM, Turley SD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol 12, 105-112.
45. Stukas S, Robert J, Lee M, Kulic I, Carr M, Tourigny K, Fan J, Namjoshi D, Lemke K, DeValle N, Chan J, Wilson T, Wilkinson A, Chapanian R, Kizhakkedathu JN, Cirrito JR, Oda MN, Wellington CL (2014) Intravenously injected human apolipoprotein A-I rapidly enters the central nervous system via the choroid plexus. J Am Heart Assoc 3, e001156.
46. Möckel B, Zinke H, Flach R, Weiss B, Weiler-Güttler H, Gassen HG (1994) Expression of apolipoprotein A-I in porcine brain endothelium in vitro. J Neurochem 62, 788-798.
47. Gosselet F, Candela P, Sevin E, Berezowski V, Cecchelli R, Fenart L (2009) Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: Use of an in vitro model. Brain Res 1249, 34-42.
48. Qosa H, Abuasal BS, Romero IA,Weksler B, Couraud PO, Keller JN, Kaddoumi A (2014) Differences in amyloid-clearance across mouse and human blood-brain barrier models: Kinetic analysis and mechanistic modeling. Neuropharmacology 79, 668-678.
49. Candela P, Saint-Pol J, Kuntz M, Boucau MC, Lamartiniere Y, Gosselet F, Fenart L (2015) In vitro discrimination of the role of LRP1 at the BBB cellular level: Focus on brain capillary endothelial cells and brain pericytes. Brain Res 1594, 15-26.
50. Zlokovic BV, Mackic JB, McComb JG, Weiss MH, Kaplowitz N, Kannan R (1994) Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 201, 402-408.
51. Jeynes B, Provias J (2008) Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 5, 432-437.
52. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, Donahue JE, Johanson CE (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 69, 1034-1043.
53. Kawano M,Kawakami M, Otsuka M,Yashima H,Yaginuma T, UekiA(1995) Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease. Clin Chim Acta 239, 209-211.
54. Saczynski JS, White L, Peila RL, Rodriguez BL, Launer LJ (2007) The relation between apolipoprotein A-I and dementia: The Honolulu-Asia aging study. Am J Epidemiol 165, 985-992.
55. Merched A, Xia Y, Visvikis S, Serot JM, Siest G (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21, 27-30.
56. Lefterov I, Fitz NF, Cronican AA, Fogg A, Lefterov P, Kodali R, Wetzel R, Koldamova R (2010) Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J Biol Chem 285, 36945-36957.
57. Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L (2010) Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem 285, 36958-36968.
58. Fitz NF, Tapias V, Cronican AA, Castranio EL, Saleem M, Carter AY, Lefterova M, Lefterov I, Koldamova R (2015) Opposing effects of Apoe/Apoa1 double deletion on amyloid-pathology and cognitive performance in APP mice. Brain 138, 3699-3715.
59. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM (2004) Antiinflammatory properties of HDL. Circ Res 95, 764-772.
60. Robert J, Stukas S, Button E, Cheng WH, Lee M, Fan J, Wilkinson A, Kulic I, Wright SD, Wellington CL (2016) Reconstituted high-density lipoproteins acutely reduce soluble brain A- levels in symptomatic APP/PS1 mice. Biochim Biophys Acta 1862, 1027-1036.